Published in Oncologist on April 03, 2012
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res (2015) 0.87
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res (2014) 0.81
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One (2014) 0.81
Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int (2015) 0.80
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer (2016) 0.78
Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions. Endocrinol Diabetes Metab Case Rep (2014) 0.76
Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review. Case Rep Endocrinol (2015) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Hypopituitarism. Lancet (2007) 2.27
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Autoantibodies to prolactin-secreting cells of human pituitary. Lancet (1975) 1.92
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol (2010) 1.73
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol (2009) 1.63
IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab (2011) 1.58
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary (2009) 1.48
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48
Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol (2010) 1.47
Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med (1993) 1.41
Lymphocytic hypophysitis: a rare or underestimated disease? Eur J Endocrinol (2003) 1.40
Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab (1995) 1.40
Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary (2006) 1.31
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.24
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother (2010) 1.24
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Pituitary autoimmunity: 30 years later. Autoimmun Rev (2008) 1.11
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist (2008) 1.05
Immunopathology of primary hypophysitis: implications for pathogenesis. Am J Surg Pathol (2005) 1.04
Hypopituitarism following radiotherapy. Pituitary (2009) 1.02
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol (2010) 1.02
Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother (2010) 0.99
Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab (2010) 0.97
Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol (2010) 0.97
Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab (2011) 0.96
From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis. Endocrinology (2011) 0.96
Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol (1998) 0.95
Lymphocytic hypophysitis. Horm Res (2007) 0.93
Reversible hypopituitarism after interferonalfa therapy. Lancet (1995) 0.93
Inflammatory and infectious processes involving the pituitary gland. Top Magn Reson Imaging (2005) 0.93
Panhypopituitarism in association with interferon-alpha treatment. Singapore Med J (2004) 0.91
Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsy-proven IgG4-related hypophysitis. Pituitary (2012) 0.90
The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev (1998) 0.90
Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol (2008) 0.88
T regulatory cells distinguish two types of primary hypophysitis. Clin Exp Immunol (2008) 0.86
Granulomatous adenohypophysitis after interferon and ribavirin therapy. Endocr Pract (2007) 0.85
Isolated gonadotrope failure in the polyglandular autoimmune syndrome. N Engl J Med (1985) 0.85
Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J Gastroenterol Hepatol (2006) 0.83
Lymphocytic adenohypophysitis. Report of a case with demonstration of spontaneous tumour regression and a review of the literature. Br J Neurosurg (1988) 0.81
Evidence for cellular mediated immunity in an animal model of autoimmune pituitary disease. Endocr Res Commun (1982) 0.81
Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides. J Clin Endocrinol Metab (1990) 0.81
Simultaneously found transient hypothyroidism due to Hashimoto's thyroiditis, autoimmune hepatitis and isolated ACTH deficiency after cessation of glucocorticoid administration. Endocr J (1997) 0.80
Lymphocytic adenohypophysitis: magnetic resonance imaging features of two new cases and a review of the literature. Clin Endocrinol (Oxf) (1995) 0.78
Induction of experimental autoimmune hypophysitis in SJL mice. J Vis Exp (2010) 0.77
Interferon-induced hypopituitarism. Am J Med (2003) 0.76
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A (2004) 1.72
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol (2009) 1.55
Images in clinical medicine. Pemberton's sign. N Engl J Med (2004) 1.47
Growth Hormone Therapy Accelerates Axonal Regeneration, Promotes Motor Reinnervation, and Reduces Muscle Atrophy following Peripheral Nerve Injury. Plast Reconstr Surg (2016) 1.43
Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42
Perioperative glucocorticoid prescribing habits in patients with inflammatory bowel disease: a call for standardization. JAMA Surg (2014) 1.37
Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res (2007) 1.36
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia. J Clin Endocrinol Metab (2002) 1.18
Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab (2006) 1.15
Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naive adults. J Clin Endocrinol Metab (2007) 1.14
Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. Mol Cell Endocrinol (2009) 1.14
A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology (2004) 1.13
Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab (2009) 1.13
Glucocorticoid-induced loss of DNA methylation in non-neuronal cells and potential involvement of DNMT1 in epigenetic regulation of Fkbp5. Biochem Biophys Res Commun (2012) 1.12
Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. Endocr Relat Cancer (2012) 1.12
Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer (2003) 1.10
Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J Clin Endocrinol Metab (2009) 1.09
On the shoulders of giants: Harvey Cushing's experience with acromegaly and gigantism at the Johns Hopkins Hospital, 1896-1912. Pituitary (2011) 1.09
Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med (2012) 1.04
Growth hormone-releasing hormone disruption extends lifespan and regulates response to caloric restriction in mice. Elife (2013) 0.97
CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid (2005) 0.97
Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev (2013) 0.96
Magnetic resonance imaging study of pituitary morphology in subjects homozygous and heterozygous for a null mutation of the GHRH receptor gene. Eur J Endocrinol (2003) 0.96
Insulin sensitivity and β-cell function in adults with lifetime, untreated isolated growth hormone deficiency. J Clin Endocrinol Metab (2011) 0.96
Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol (2016) 0.96
Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev (2014) 0.94
Heterozygosity for a mutation in the growth hormone-releasing hormone receptor gene does not influence adult stature, but affects body composition. J Clin Endocrinol Metab (2007) 0.92
Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother (2004) 0.92
Expanded endonasal endoscopic approach for resection of a growth hormone-secreting pituitary macroadenoma coexistent with a cavernous carotid artery aneurysm. J Clin Neurosci (2012) 0.91
Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab (2014) 0.91
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol (2013) 0.90
Adipokine profile and urinary albumin excretion in isolated growth hormone deficiency. J Clin Endocrinol Metab (2009) 0.89
Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res (2004) 0.89
Complications and death among elderly patients undergoing pituitary tumour surgery. Clin Endocrinol (Oxf) (2010) 0.88
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens (2015) 0.88
Isolated GH deficiency due to a GHRH receptor mutation causes hip joint problems and genu valgum, and reduces size but not density of trabecular and mixed bone. J Clin Endocrinol Metab (2013) 0.87
Pituitary antibodies in women with Hashimoto's thyroiditis: prevalence in diagnostic and prediagnostic sera. Thyroid (2012) 0.87
Pituitary and systemic autoimmunity in a case of intrasellar germinoma. Pituitary (2009) 0.86
Predictors of access to pituitary tumor resection in the United States, 1988-2005. Eur J Endocrinol (2009) 0.84
Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res (2014) 0.84
Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog Mol Biol Transl Sci (2009) 0.84
Effects of recombinant mouse growth hormone treatment on growth and body composition in GHRH knock out mice. Growth Horm IGF Res (2005) 0.83
Clinical features of sellar and suprasellar meningiomas. Pituitary (2014) 0.83
Video-assisted minimally invasive parathyroidectomy: benefits and long-term results. World J Surg (2009) 0.83
Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev (2010) 0.82
Prognostic value of exercise echocardiography in diabetic patients. Cardiovasc Ultrasound (2009) 0.82
ACTH-secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol (Oxf) (2012) 0.82
Periodontal disease in adults with untreated congenital growth hormone deficiency: a case-control study. J Clin Periodontol (2011) 0.82
Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog. Endocrinology (2004) 0.82
Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res (2008) 0.82
Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene. Clin Endocrinol (Oxf) (2008) 0.82
Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocr Connect (2013) 0.82
Prevalence of antipituitary antibodies in acromegaly. Pituitary (2012) 0.81
Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther (2011) 0.81
Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary (2011) 0.81
Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol (Oxf) (2007) 0.81
Increased visceral adiposity and cortisol to cortisone ratio in adults with congenital lifetime isolated GH deficiency. J Clin Endocrinol Metab (2014) 0.81
Expression of the pituitary stem/progenitor marker GFRα2 in human pituitary adenomas and normal pituitary. Pituitary (2015) 0.80
Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene. Vitam Horm (2004) 0.80
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol (2013) 0.80
Thyroid morphology and function in adults with untreated isolated growth hormone deficiency. J Clin Endocrinol Metab (2006) 0.80
Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid (2013) 0.80
Variability in anterior pituitary size within members of a family with GH deficiency due to a new splice mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) (2004) 0.80
Visual vignette. Thyrotroph cell hyperplasia. Endocr Pract (2012) 0.80
Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab (2005) 0.79
Climacteric in untreated isolated growth hormone deficiency. Menopause (2008) 0.79
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab (2006) 0.79
A single injection of double-stranded adeno-associated viral vector expressing GH normalizes growth in GH-deficient mice. J Endocrinol (2008) 0.79
Vitamin A deficiency does not influence longitudinal growth in mice. Nutrition (2007) 0.79
Lingual thyroid. Endocrine (2013) 0.79
Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. Pituitary (2013) 0.79
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Thyroid (2009) 0.79
Pituitary tumors. Curr Treat Options Neurol (2009) 0.79
The role of adrenal scintigraphy in the diagnosis of subclinical Cushing's syndrome and the prediction of post-surgical hypoadrenalism. World J Surg (2014) 0.79
A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. Eur J Endocrinol (2003) 0.79
Long- but not short-term adult-onset, isolated GH deficiency in male mice leads to deterioration of β-cell function, which cannot be accounted for by changes in β-cell mass. Endocrinology (2013) 0.79
Molecular and clinical aspects of GHRH receptor mutations. Endocr Dev (2013) 0.79
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro. Anticancer Res (2004) 0.78
Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. J Exp Clin Cancer Res (2010) 0.78
[Growth or somatotrophic hormone: new perspectives in isolated GH deficiency after description of the mutation in the GHRH receptor gene in individuals of Itabaianinha County, Brazil]. Arq Bras Endocrinol Metabol (2004) 0.78
Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) (2008) 0.78
Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature. BMC Endocr Disord (2014) 0.78
Laryngeal and vocal evaluation in untreated growth hormone deficient adults. Otolaryngol Head Neck Surg (2009) 0.78
Giant somatotrophinoma without acromegalic features: more "quiet" than "silent": case report. Neurosurgery (2005) 0.78
Influence of estrogen administration on the growth response to growth hormone (GH) in GH-deficient mice. Exp Biol Med (Maywood) (2005) 0.78
Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse. Neuroendocrinology (2006) 0.78
Adult-onset growth hormone deficiency: causes, complications and treatment options. Curr Opin Endocrinol Diabetes Obes (2008) 0.77
Naturally-occurring missense mutations in the human growth hormone-releasing hormone receptor alter ligand binding. J Endocrinol (2005) 0.77
Cephalometric features in isolated growth hormone deficiency. Angle Orthod (2011) 0.77